Longeveron LLC (LGVN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $8.40M
Last updated: Nov 17, 2026 at 11:03 AM ET
Longeveron LLC (LGVN) Competitors
The companies most similar to Longeveron LLC are Biovie (BIVI), Enveric Biosciences (ENVB) and Vyome Holdings (HIND). By market cap, Longeveron LLC ranks 4th of the 13 companies on this page; Pluri (PLUR) is the largest at $15.09M.
Peer Comparison
LGVN's revenue growth of -9.2% is below the peer median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Longeveron LLC (LGVN) | $8.40M | N/A | 5.9x | 0.0% | N/A | -9.2% | 0.00% |
| Biovie Inc (BIVI) | $12.12M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Enveric Biosciences Inc (ENVB) | $6.78M | N/A | 0.2x | 0.0% | N/A | -7.3% | 0.00% |
| Vyome Holdings, Inc. (HIND) | $11.09M | N/A | N/A | 0.0% | N/A | 67.5% | 0.00% |
| FibroBiologics, Inc. Common Stock (FBLG) | $6.57M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Theriva Biologics Inc. (TOVX) | $6.61M | N/A | 21.5x | 0.0% | -52.3% | 0.0% | 0.00% |
| Moleculin Biotech Inc (MBRX) | $8.02M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN) | $4.02M | N/A | N/A | 0.0% | -247.2% | 0.0% | 0.00% |
| Pluri Inc. (PLUR) | $15.09M | N/A | 8.7x | 0.0% | -650.8% | -15.8% | 0.00% |
| Tempest Therapeutics Inc (TPST) | $7.64M | N/A | N/A | 0.0% | -783.6% | 0.0% | 0.00% |
| Soligenix Inc. (SNGX) | $7.50M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| GT Biopharma Inc (GTBP) | $7.67M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Lantern Pharma Inc (LTRN) | $6.47M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Peer median | $7.57M | N/A | 8.7x | 0.0% | -449.0% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Longeveron LLC, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Biovie Inc (BIVI) | BioVie Inc., a clinical-stage biotechnology company, is dedicated to the discovery, development, and commercialization of drug therapies in the United States. | BIVI competitors |
| Enveric Biosciences Inc (ENVB) | Enveric Biosciences, Inc., a pharmaceutical company, is dedicated to developing various cannabinoid drugs for the treatment of cancer. | ENVB competitors |
| Vyome Holdings, Inc. (HIND) | Vyome Holdings Inc., a clinical-stage healthcare company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States... | HIND competitors |
| FibroBiologics, Inc. Common Stock (FBLG) | FibroBiologics, Inc. is an innovative biotechnology company dedicated to advancing regenerative medicine through its proprietary fibroblast cell technology... | FBLG competitors |
| Theriva Biologics Inc. (TOVX) | Theriva Biologics Inc., a clinical-stage company, develops therapies to treat diseases in areas of high unmet need. | TOVX competitors |
| Moleculin Biotech Inc (MBRX) | Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of cancer drug candidates for the treatment of highly resistant... | MBRX competitors |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN) | Liminatus Pharma, Inc. is a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is headquartered in LA Palma, California. | LIMN competitors |
| Pluri Inc. (PLUR) | Pluri Inc. is an innovative biotechnology company at the forefront of regenerative medicine and immunotherapy... | PLUR competitors |
| Tempest Therapeutics Inc (TPST) | Tempest Therapeutics Inc., a clinical-stage oncology company, is dedicated to the development of small molecules that combine targeted and immune-mediated... | TPST competitors |
| Soligenix Inc. (SNGX) | Soligenix, Inc., an advanced stage biopharmaceutical company, focuses on developing and marketing products to treat rare diseases in the United States. | SNGX competitors |
| GT Biopharma Inc (GTBP) | GT Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its... | GTBP competitors |
| Lantern Pharma Inc (LTRN) | Lantern Pharma Inc., a clinical-stage biotechnology company, focuses on developing precision cancer therapies using artificial intelligence, genomics... | LTRN competitors |
Frequently Asked Questions About LGVN
Who are Longeveron LLC's main competitors?
The companies most similar to Longeveron LLC include Biovie (BIVI), Enveric Biosciences (ENVB), Vyome Holdings (HIND), FibroBiologics, Inc. Common Stock (FBLG) and Theriva Biologics (TOVX), listed from the closest match.
Who is Longeveron LLC's biggest competitor?
Pluri (PLUR) is the largest of the similar companies at $15.09M; Biovie (BIVI) is the closest match by business profile, size, sector and industry.
How does LGVN stock compare with its competitors?
LGVN's P/S is 5.9x against a peer median of 8.7x; its net margin is 0.0% against a peer median of 0.0%.
Which of Longeveron LLC's competitors pays a higher dividend?
Longeveron LLC pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Longeveron LLC bigger than its competitors?
No. Longeveron LLC is 4th by market cap among the 13 companies on this page; the largest is Pluri (PLUR) at $15.09M.
LGVN pages: Overview, Earnings, Forecast, Financials, Competitors